The invention provides compositions and methods for generating improved T cells having increased Ezh2 activity and methods of use thereof in the treatment of cancer and chronic infection.

Provided herein are compositions and methods related to the production and detection of a histone H1.0 protein dimethylated at lysine residue 180 (K180) (H1.0K180me2 protein) or a histone H1.0 peptide dimethylated at a lysine residue corresponding to K180 (H1.0K180me2 peptides). The H1.0K180me2 protein and H1.0K180me2 peptides are useful for applications including, but not limited to, molecular diagnostics of DNA damage, genotoxic stress, radiation exposure, and Alzheimer's disease, therapeutics, monitoring of therapeutic regimens, patient stratification, and drug screening. Also provided herein are antibodies specific for the H1.0K180me2 protein and H1.0K180me2 peptides.

This invention relates to long non-coding RNAs (lncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting lncRNAs.

This invention relates to long non-coding RNAs (lncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting lncRNAs.

Provided herein are methods for diagnosing cancer by determining the level of expression of SETDB1 in a biological sample. Also provided herein are methods for treating cancer by administering an inhibitor of SETDB1 to a subject in need thereof.

Methods for identifying and developing biomarkers based on the characterization of disease-related components of gene-specific chromatin regulatory protein complexes. Chemoprobes that are substrate-competitive and selectively bind enzymatically active enzymes associated with gene-specific chromatin regulatory protein complex can be used to select chromatin complexes associated with a phenotype of interest.

Provided is a composition for controlling pluripotency of stem cells including an LIN28A methylation inhibitor and a screening method of the LIN28A methylation inhibitor, and more particularly, a composition for controlling pluripotency of stem cells including an inhibitor controlling methylation of 135.sup.th lysine of LIN28A that is methylated by SET7/9, or a composition for treating cancer, and a screening method of the inhibitor, wherein the screening method includes (a) contacting a candidate material with a cell, the cell having a gene introduced thereinto; (b) measuring a methylation level of the 135.sup.th lysine of the LIN28A; and (c) selecting an inhibitor controlling methylation of the 135.sup.th lysine of the LIN28A. That is, the present invention relates to a composition for controlling pluripotency of embryonic stem cells, or an anti-cancer composition, and a screening method of the inhibitor. The method of the present invention is possible to screen materials capable of controlling pluripotency of embryonic stem cells or materials having anti-cancer activity, and the materials screened by the method of the present invention may control pluripotency of embryonic stem cells and inhibit growth of cancer cells, which is effective for disorders of stem cell differentiation or preparation of cancer therapeutic agents.

The present invention relates to compositions and methods for the detecting, treating, and empirically investigating the interaction between a subject's immune system and cancer stem cells. In particular, the present invention provides compositions and methods for using IL-22 cytokine signaling and/or downstream targets of IL-22 cytokine signaling (e.g., STAT3, DOT1L, SUZ12, EED) in the diagnosis, treatment, and empirical investigation of cancers characterized with cancer stem cells activated through IL-22 cytokine signaling.

Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenotnic engineering, genome targeting, and genome editing.

This invention relates to long non-coding RNAs (lncRNAs), libraries of those lncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting lncRNAs.